Scientific Publications

Draper SJ, Heeney JL.. Viruses as vaccine vectors for infectious diseases and cancer.. 2010. Nat Rev Microbiol. 2010 Jan 8(1):62-73. PubMed

Levy Y, Ellefsen K, Stöehr W, Bart P-A, Lelièvre J-D, Launay O, Wolf H, Weber J, Chêne G and Pantaleo G. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injections. Results of the randomized multicentre EV03/ANRS Vac20 Phase I/II Trial.. 2010. CROI.

Mooij P, Balla-Jhagjhoorsingh SS, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, Heidar S, Wolf H, Frachette M-J, Bieler K, Sheppard N, Harari A, Bart PA, Liljeström P, Wagner R, Pantaleo G and Heeney JL. Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding HIV-1 clade C immunogens. 2009. Journal of Virology 83 (11): p.5881-9. PubMed

Bart P-A, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, Sheppard N.C, Bangala Y, Frachette M-J, Wagner R, Liljeström P, Kraehenbuhl J-P, Girard M, Goudsmit J, Esteban M, Heeney J, Sattentau Q, McCormack S, Babiker A, Pantaleo G and Weber. EV01: A phase 1 trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. 2008. Vaccine. 26; p.3153-61. PubMed

Bart P-A, Harari A, Vermeulen J, Bellutti Enders F, Castro E, Cavassini M, Wit F, Autran B, Lange J and Pantaleo G. TheraVac-01: Evaluation of safety and immunogenicity of the HIV-1 vaccine NYVAC-B in chronic HIV-1 infected patients successfully treated with HAART. 2008. AIDS Vaccine Conference Cape Town, South Africa.

Corbett M, Bogers W.M., Heeney J.L, Gerber S, Genin C, Didierlaurent A, Oostermeijer H, Dubbes R, Braskamp G, Lerondel S, Gómez C.E, Esteban M, Wagner R, Kondova I, Mooij P, Balla-Jhagjhoorsingh S, Beenhakker N, Koopman G, Van den Berg S, Kraenhenbuhl J-P. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple and immunogenic. 2008. Proceedings of the National Academy of Scienses. 105 (6); p. 2046–51. PubMed

Gómez C.E, Nájera J.L, Krupa M and Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. 2008. Gene Therapy. 8; p. 97-120. PubMed

Harari A, Bart P-A, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljeström P, Wagner R, Wolf H, Kraenhenbuhl J-P, Esteban M, Heeney J, Frachette M-J, Tartaglia J, McCormack S, Babiker A, Weber J and Panta. A HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. 2008. The Journal of Experimental Medicine. 205(1); p. 7-12. PubMed

McCormack S, Stöhr W, Barber T, Bart P-A, Harari A, Moog C, Ciuffreda D, Cellerai C, Cowen M, Gamboni R, Burnet S, Legg K, Brodnicki E, Wolf H, Wagner R, Heeney J, Frachette M-J, Tartaglia J, Babiker A, Pantaleo G, Weber J. EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime –NYVAC-C boost to NYVAC-C alone. 2008. Vaccine. 26; p. 3162-74. PubMed

Mooij P, Balla-Jhagjhoorsingh S.S, Koopman G, Beenhakker N, Van Haaften P, Baak I, Nieuwenhuis I.G, Kondova I, Wagner R, Wolf H, Gómez C.E, Nájera J.L, Jiménez V, Esteban M and Heeney J.L. Differential CD4+ versus CD8+ responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. 2008. Journal of Virology. 82(6); p. 2975-88. PubMed

Vermeulen J, Bart P-A, Nanlohy N, Van Baarle D, Wit F, Miedema F, Pantaleo G, Autran B, Lange J and TheraVac study group. TheraVac-02: An open-label phase I study to evaluate the safety of the HIV-1 vaccine MVA-B in chronic HIV-1 infected patients successfully treated with HAART. 2008. World AIDS Congress Mexico City, Mexico.

Verstrepen BE, Bins AD, Rollier CS, Mooij P, Koopman G, Sheppard NC, Sattentau Q, Wagner R, Wolf H, Schumacher TN, Heeney JL and Haanen JB. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. 2008. Vacccine. 26 (26); p. 3346-51. PubMed

Gómez C.E, Nájera J.L, Domingo-Gil E, Ochoa-Callejero L, González-Aseguinolaza G and Esteban M. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. 2007. Journal of General Virology. 88; p. 2473-78. PubMed

Gómez C.E, Nájera J.L, Jiménez V, Bieler K, Wild J, Kostic L, Heidare S, Chen M, Frachette M-J, Pantaleo G, Wolf H, Liljeström P, Wagner R and Esteban M. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. 2007. Vaccine. 25 (11); p. 1969-92. PubMed

Gómez C.E, Nájera J.L, Jiménez V, Wagner R, Graf M, Frachette M-J, Liljeström P, Pantaleo G and Esteban M. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1 BX08 gp120 and HIV-1 IIIB Gag-Pol-Nef proteins of clade B. 2007. Vaccine. 25 (15); p. 2863-85. PubMed

Guerra S, López-Fernández L.A, Pascual-Montano A, Nájera J.L, Zaballos A and Esteban M. Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kB-responsive genes in infected HeLa cells. 2006. Journal of Virology. 80; p. 985-998. PubMed

Nájera J.L, Gómez C.E, Domingo E, Gherardi M.M and Esteban M. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of C7L gene. 2006. Journal of Virology. 80; p. 6033-6047. PubMed

Bogers W, Bergmeier L, Oostermeijer H, Wang Y, Kelly C, ten Haaft P, Singh M, Heeney J, Lehner T. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV infection. 2004. AIDS. 200; p. 1825-36. PubMed

Balla-Jhagjhoorsingh SS, Verschoor EJ, de Groot N, Teeuwsen VJP, Bontrop RE, Heeney JL. Specific nature of cellular immune responses elicited by chimpanzees against HIV-1. 2003. Human Imm. 64; p. 681-688. PubMed

Ramirez, J. C., Finke, D., Esteban, M., Kraehenbuhl, J. P., and Acha-Orbea, H. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. 2003. Archives of Virology. 148; p. 827-839. PubMed